MDT
Medtronic plc
MDT's fundamentals are strong: it turned 16% of its revenue into free cash flow and revenue grew 9.8%. At 25x earnings, it's trading in line with its usual 27x. Analysts expect earnings growth.
MDT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Stable |
MDT's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
MDT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $101 | — |
| Cheap | 24x | $98.52 | -2.4% |
| Current | 25x | $101 | — |
| Fair | 27x | $111 | +9.9% |
| Expensive | 33x | $135 | +34% |
Historical ranges are pointers, not guarantees.
MDT's PE is in its cheap range at 25x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
MDT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for MDT, with profitability improving.
MDT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.16 | +52% |
| Q3 2026 | $4.06 | +12% |
| Q2 2026 | $3.73 | +3.3% |
| Q1 2026 | $3.58 | +8.5% |
| Q4 2025 | $3.70 | +13% |
| Q3 2025 | $3.62 | +22% |
| Q2 2025 | $3.61 | +31% |
| Q1 2025 | $3.30 | +5.1% |
| Q4 2024 | $3.28 | +6.8% |
MDT's earnings per share have climbed steadily: $4.06 over the past year, up 12% from the year before, and higher year over year for nine quarters in a row.
MDT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.8B | +14% |
| Q2 2026 | $9.8B | +9.9% |
| Q1 2026 | $9B | +8.7% |
| Q4 2025 | $9B | +6.6% |
| Q3 2025 | $8.6B | +8.4% |
| Q2 2025 | $8.9B | +3.9% |
| Q1 2025 | $8.3B | +2.5% |
| Q4 2024 | $8.4B | +5.2% |
MDT's revenue has grown year over year for 14 quarters in a row: $9.8B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +1.2 points |
| Q2 2026 | 19% | +3 points |
| Q1 2026 | 16% | -3.6 points |
| Q4 2025 | 19% | -0.2 points |
| Q3 2025 | 17% | +0.7 points |
| Q2 2025 | 16% | +3.8 points |
| Q1 2025 | 20% | +1.5 points |
| Q4 2024 | 19% | +2.2 points |
MDT's operating margin was 18% last quarter, up 1.2 points from the same quarter a year ago.
MDT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +121% |
| Q2 2026 | $2.1B | +0.8% |
| Q1 2026 | $2.3B | +9.7% |
| Q4 2025 | $457M | -18% |
| Q3 2025 | $584M | +25% |
| Q2 2025 | $2.1B | -12% |
| Q1 2025 | $2.1B | -1.5% |
| Q4 2024 | $554M | +177% |
MDT generated $6.1B in free cash flow over the past year, up 16% from the year before.
MDT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -0.2% | -2M shares |
| 3 years | -3.7% | -48.7M shares |
| 5 years | -5.3% | -71.3M shares |
| Available history | -4.9% | -66.3M shares |
MDT has 1.3B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $267M |
| Q2 2026 | $435M |
| Q1 2026 | $105M |
| Q4 2025 | $372M |
| Q3 2025 | $123M |
| Q2 2025 | $274M |
| Q1 2025 | $181M |
| Q4 2024 | $288M |
MDT spent $1.2B buying back its own shares over the past year, up 36% from the year before.
MDT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.7x | Moderate |
| Q2 2026 | 2.8x | Moderate |
| Q1 2026 | 3.0x | Moderate |
| Q4 2025 | 3.0x | Elevated |
| Q3 2025 | 3.0x | Elevated |
| Q2 2025 | 3.0x | Moderate |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 3.4x | Elevated |
MDT's net debt is about 2.7 years of its operating earnings (EBITDA), down from 3.0 years a year ago.
MDT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.9 | Neutral |
| Stochastic | 81.3 | Overbought |
MDT's weekly RSI is 66 (neutral) and its Stochastic is 81 (overbought).
MDT PE vs Healthcare Sector
| Metric | MDT | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 3.8% below |
| PE % | 22 | 29 | 7 pts below |
MDT is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
MDT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $94.1 | 7.3% above |
| 20 week MA | $90.6 | 11% above |
| 50 week MA | $90.0 | 12% above |
| 100 week MA | $89.9 | 12% above |
| 200 week MA | $86.6 | 17% above |
MDT is in an uptrend: it's above all five of its weekly moving averages, and 17% above its 200-week average.
MDT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $113.4 | $114.0 | +0.6% |
| 2021 | $114.0 | $102.9 | -9.8% |
| 2022 | $102.9 | $77.5 | -25% |
| 2023 | $77.5 | $82.4 | +6.3% |
| 2024 | $82.4 | $80.7 | -2% |
| 2025 | $80.7 | $96.5 | +20% |
| 2026 YTD | $96.5 | $101.0 | +4.6% |
MDT has finished lower in three of the last six years. It's up 4.6% so far in 2026.